mimmunМедицинская иммунологияMedical Immunology (Russia)1563-06252313-741XSPb RAACI10.15789/1563-0625-2011-2-3-285-290mimmun-528Research ArticleКРАТКИЕ СООБЩЕНИЯSHORT COMMUNICATIONSВЛИЯНИЕ МЕВАСТАТИНА И БИОЛОГИЧЕСКИХ ПРЕПАРАТОВ НА АКТИВАЦИЮ ВЭБ-СПЕЦИФИЧНЫХ CD4+ ЛИМФОЦИТОВ У БОЛЬНЫХ РЕВМАТОИДНЫМ АРТРИТОМ IN VITROIN VITRO EFFECTS OF MEVASTATIN AND BIOLOGICAL PREPARATIONS UPON ACTIVATION OF EBV-SPECIFIC CD4+T LYMPHOCYTES FROM THE PATIENTS WITH RHEUMATOID ARTHRITISШиринскийИ. В.ShirinskyI. V.

Лаборатория клинической иммунофармакологии

630099, г. Новосибирск, ул. Ядринцевская, 14.

ishirinsky@mail.ruШиринскийВ. С.ShirinskyV. S.

Лаборатория клинической иммунофармакологии

ishirinsky@mail.ruDinarelloC. A.DinarelloC. A.ishirinsky@mail.ruРоссийская академия медицинских наук Научно-исследовательского института клинической иммунологии СО РАМН, г. НовосибирскRussian FederationDivision of Infectious Diseases, University of Colorado Health Sciences Center, DenverRussian Federation201122072014132-3285290Copyright © Ширинский И.В., Ширинский В.С., Dinarello C.A., 20142014Ширинский И.В., Ширинский В.С., Dinarello C.A.Shirinsky I.V., Shirinsky V.S., Dinarello C.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.mimmun.ru/mimmun/article/view/528Резюме

Резюме. Изучалось влияние мевастатина, инфликсимаба, r-met-Hu-sTNF-RI и IL-1ra на антигениндуцированную  активацию  ВЭБ-специфичных  CD4+T-лимфоцитов  у  больных  РА.  Показано, что  у  больных  РА,  по  сравнению  со  здоровыми  людьми,  содержание  ВЭБ-специфичных  CD4+T-лимфоцитов достоверно ниже. У здоровых доноров инфликсимаб, r-met-Hu-sTNF-RI и IL-1ra не влияли на активацию ВЭБ-специфичных CD4+ лимфоцитов. Добавление в культуры МНК ПК больных РА мевастатина, инфликсимаба, r-met-Hu-sTNF-RI или IL-1ra также не приводило к статистически значимым изменениям концентрации CD4+, IFNγ+ клеток. Таким образом, у больных РА выявляется снижение антигениндуцированной активации ВЭБ-специфичных CD4+ лимфоцитов, а статины и биологические препараты не способствуют ее дальнейшему подавлению. 

 

 

Abstract

Abstract. Present study concerned in vitro modifying effects of mevastatin, infliximab, r-met-Hu-sTNF-RI and IL-1ra upon antigen-induced activation of peripheral EBV-specific CD4+T-lymphocytes from the patients with rheumatoid arthritis (RA). When compared with healthy persons, the RA patients have shown significantly decreased  concentrations  of  antigen-activated  EBV-specific  CD4+T-cells.  In  healthy  donors,  mevastatin, infliximab, r-met-Hu-sTNF-RI and IL-1ra did not influence the CD4+, IFNγ+ cell concentrations. Neither there were any effects of the abovementioned drugs upon the numbers of EBV-specific CD4+T-cell subset among cultured  mononuclear  cells  from  RA  patients.  Thus,  the  cells  from  RA  patients  exhibit  a  decreased  in  vitro antigen-induced activation of EBV-specific CD4+T-cells, whereas statins and biological agents do not promote suppression of EBV-specific activation of CD4+T-cells. (Med. Immunol., 2011, vol. 13, n 2-3, pp 285-290)

 

 

ревматоидный артритвирус Эпштейна–Баррлечениестатиныбиологические препаратыrheumathoid arthritisEpstein–Barr virustreatmentstatinsbiological drugsReferencesШиринский И.В., Желтова О.И., Соловьева Н.Ю., Ширинский В.С. Влияние статинов на пролиферацию лимфоцитов при ревматоидном артрите // Аллергология и иммунология. – 2007. – № 4. – С. 380-383.Ширинский И.В., Желтова О.И., Соловьева Н.Ю., Ширинский В.С. Влияние статинов на пролиферацию лимфоцитов при ревматоидном артрите // Аллергология и иммунология. – 2007. – № 4. – С. 380-383.Ширинский И.В., Желтова О.И., Соловьева Н.Ю., Ширинский В.С., Козлов В.А. Эффективность и безопасность симвастатина при ревматоидном артрите – открытое контролируемое исследование // Медицинская иммунология. – 2007. – № 4-5. – С. 477-482.Ширинский И.В., Желтова О.И., Соловьева Н.Ю., Ширинский В.С., Козлов В.А. Эффективность и безопасность симвастатина при ревматоидном артрите – открытое контролируемое исследование // Медицинская иммунология. – 2007. – № 4-5. – С. 477-482.Asten P., Barrett J., Symmons D. Risk of developing certain malignancies is related to duration of immunosuppressive drug exposure in patients with rheumatic diseases // J. Rheumatol. – 1999. – Vol. 26. – P. 1705-1714.Asten P., Barrett J., Symmons D. Risk of developing certain malignancies is related to duration of immunosuppressive drug exposure in patients with rheumatic diseases // J. Rheumatol. – 1999. – Vol. 26. – P. 1705-1714.Aversa G., Punnonen J., de Vries J.E. The 26-kD transmembrane form of tumor necrosis factor alpha on activated CD4+ T cell clones provides a costimulatory signal for human B cell activation // J. Exp. Med. – 1993. – Vol. 177. – P. 1575-1585.Aversa G., Punnonen J., de Vries J.E. The 26-kD transmembrane form of tumor necrosis factor alpha on activated CD4+ T cell clones provides a costimulatory signal for human B cell activation // J. Exp. Med. – 1993. – Vol. 177. – P. 1575-1585.Baecklund E., Askling J., Rosenquist R., Ekbom A., Klareskog L. Rheumatoid arthritis and malignant lymphomas // Curr. Opin. Rheumatol. – 2004. – Vol. 16. – P. 254-261.Baecklund E., Askling J., Rosenquist R., Ekbom A., Klareskog L. Rheumatoid arthritis and malignant lymphomas // Curr. Opin. Rheumatol. – 2004. – Vol. 16. – P. 254-261.Balandraud N., Roudier J., Roudier C. Epstein–Barr virus and rheumatoid arthritis // Autoimmun Rev. – 2004. – Vol. 3. – P. 362-367.Balandraud N., Roudier J., Roudier C. Epstein–Barr virus and rheumatoid arthritis // Autoimmun Rev. – 2004. – Vol. 3. – P. 362-367.Feng W.H., Cohen J.I., Fischer S., Li L., Sneller M., Goldbach-Mansky R., Raab-Traub N., Delecluse H.J., Kenney S.C. Reactivation of latent Epstein–Barr virus by methotrexate: a potential contributor to methotrexate-associated lymphomas // J. Natl. Cancer Inst. – 2004. – Vol. 96. – P. 1691-1702.Feng W.H., Cohen J.I., Fischer S., Li L., Sneller M., Goldbach-Mansky R., Raab-Traub N., Delecluse H.J., Kenney S.C. Reactivation of latent Epstein–Barr virus by methotrexate: a potential contributor to methotrexate-associated lymphomas // J. Natl. Cancer Inst. – 2004. – Vol. 96. – P. 1691-1702.Hober D., De Groote D., Vanpouille N., Dehart I., Shen L., Wattre P., Maniez-Montreuil M. Tumor necrosis factor receptor expression in HIV1-infected CD4+ T cells // Microbiol. Immunol. – 1994. – Vol. 38. – P. 1005-1008.Hober D., De Groote D., Vanpouille N., Dehart I., Shen L., Wattre P., Maniez-Montreuil M. Tumor necrosis factor receptor expression in HIV1-infected CD4+ T cells // Microbiol. Immunol. – 1994. – Vol. 38. – P. 1005-1008.Jones M., Symmons D., Finn J., Wolfe F. Does exposure to immunosuppressive therapy increase the 10 year malignancy and mortality risks in rheumatoid arthritis? A matched cohort study // Br. J. Rheumatol. – 1996. – Vol. 35. – P. 738-745.Jones M., Symmons D., Finn J., Wolfe F. Does exposure to immunosuppressive therapy increase the 10 year malignancy and mortality risks in rheumatoid arthritis? A matched cohort study // Br. J. Rheumatol. – 1996. – Vol. 35. – P. 738-745.Knowles D.M. Etiology and pathogenesis of AIDS-related non-Hodgkin's lymphoma // Hematol. Oncol. Clin. North Am. – 2003. – Vol. 17. – P. 785-820.Knowles D.M. Etiology and pathogenesis of AIDS-related non-Hodgkin's lymphoma // Hematol. Oncol. Clin. North Am. – 2003. – Vol. 17. – P. 785-820.Lejeune F.J., Ruegg C., Lienard D. Clinical applications of TNF-alpha in cancer // Curr. Opin. Immunol. – 1998. – Vol. 10. – P. 573-580.Lejeune F.J., Ruegg C., Lienard D. Clinical applications of TNF-alpha in cancer // Curr. Opin. Immunol. – 1998. – Vol. 10. – P. 573-580.Mariette X., Tubach F., Bagheri H., Bardet M., Berthelot J.M., Gaudin P., Heresbach D., Martin A., Schaeverbeke T., Salmon D., Lemann M., Hermine O., Raphael M., Ravaud P. Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry // Ann. Rheum. Dis. – Vol. 69. – P. 400-408.Mariette X., Tubach F., Bagheri H., Bardet M., Berthelot J.M., Gaudin P., Heresbach D., Martin A., Schaeverbeke T., Salmon D., Lemann M., Hermine O., Raphael M., Ravaud P. Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry // Ann. Rheum. Dis. – Vol. 69. – P. 400-408.Nissinen R., Leirisalo-Repo M., Peltomaa R., Palosuo T., Vaarala O. Cytokine and chemokine receptor profile of peripheral blood mononuclear cells during treatment with infliximab in patients with active rheumatoid arthritis // Ann. Rheum. Dis. – 2004. – Vol. 63. – P. 681-687.Nissinen R., Leirisalo-Repo M., Peltomaa R., Palosuo T., Vaarala O. Cytokine and chemokine receptor profile of peripheral blood mononuclear cells during treatment with infliximab in patients with active rheumatoid arthritis // Ann. Rheum. Dis. – 2004. – Vol. 63. – P. 681-687.Orosz P., Echtenacher B., Falk W., Ruschoff J., Weber D., Mannel D.N. Enhancement of experimental metastasis by tumor necrosis factor // J. Exp. Med. – 1993. – Vol. 177. – P. 1391-1398.Orosz P., Echtenacher B., Falk W., Ruschoff J., Weber D., Mannel D.N. Enhancement of experimental metastasis by tumor necrosis factor // J. Exp. Med. – 1993. – Vol. 177. – P. 1391-1398.Paludan C., Munz C. CD4+ T cell responses in the immune control against latent infection by Epstein–Barr virus // Curr Mol Med. – 2003. – Vol. 3. – P. 341-347.Paludan C., Munz C. CD4+ T cell responses in the immune control against latent infection by Epstein–Barr virus // Curr Mol Med. – 2003. – Vol. 3. – P. 341-347.Shirinsky I.V., Zheltova O.I., Solovyova N.Y., Kozlov V.A., Shirinsky V.S. Changes in disease activity, cytokine production, and proliferation of peripheral blood mononuclear cells in patients with rheumatoid arthritis after simvastatin treatment // Scand. J. Rheumatol. – 2009. – Vol. 38. – P. 23-27.Shirinsky I.V., Zheltova O.I., Solovyova N.Y., Kozlov V.A., Shirinsky V.S. Changes in disease activity, cytokine production, and proliferation of peripheral blood mononuclear cells in patients with rheumatoid arthritis after simvastatin treatment // Scand. J. Rheumatol. – 2009. – Vol. 38. – P. 23-27.Siebert F., Kalden J.R., Fink P., Fricke M., Deicher H. The effect of serum and allogeneic antiglobulin preparations on the mitogenic reactivity of peripheral blood lymphocytes from patients with rheumatoid arthritis // Z. Rheumatol. – 1978. –Vol. 37. – P. 286-295.Siebert F., Kalden J.R., Fink P., Fricke M., Deicher H. The effect of serum and allogeneic antiglobulin preparations on the mitogenic reactivity of peripheral blood lymphocytes from patients with rheumatoid arthritis // Z. Rheumatol. – 1978. –Vol. 37. – P. 286-295.Van den Brande J.M., Braat H., van den Brink G.R., Versteeg H.H., Bauer C.A., Hoedemaeker I., van Montfrans C., Hommes D.W., Peppelenbosch M.P., van Deventerм S.J. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease // Gastroenterology. – 2003. – Vol. 124. – P. 1774-1785. 19. Wolfe F.,Michaud K. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients uring 89,710 person-years of observation // Arthritis Rheum. – 2007. – Vol. 56. – P. 1433-1439.Van den Brande J.M., Braat H., van den Brink G.R., Versteeg H.H., Bauer C.A., Hoedemaeker I., van Montfrans C., Hommes D.W., Peppelenbosch M.P., van Deventerм S.J. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease // Gastroenterology. – 2003. – Vol. 124. – P. 1774-1785. 19. Wolfe F.,Michaud K. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients uring 89,710 person-years of observation // Arthritis Rheum. – 2007. – Vol. 56. – P. 1433-1439.Wolfe А., Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-TNF therapy in 18 572 patients // Arthritis Rheum. – 2003. – Vol. 48 (suppl.). – P. 242.Wolfe А., Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-TNF therapy in 18 572 patients // Arthritis Rheum. – 2003. – Vol. 48 (suppl.). – P. 242.

The authors declare that there are no conflicts of interest present.